|1.||Tschernig, Thomas: 8 articles (12/2015 - 03/2003)|
|2.||Mühlradt, Peter F: 6 articles (09/2015 - 09/2005)|
|3.||Roth, Joachim: 4 articles (06/2012 - 01/2006)|
|4.||Gerstberger, Rüdiger: 4 articles (06/2012 - 01/2006)|
|5.||Pabst, Reinhard: 4 articles (02/2010 - 03/2003)|
|6.||Grote, Karsten: 3 articles (09/2013 - 03/2003)|
|7.||Hübschle, Thomas: 3 articles (06/2012 - 01/2006)|
|8.||Lührmann, Anke: 3 articles (02/2010 - 03/2003)|
|9.||Mühlradt, P F: 3 articles (09/2007 - 03/2004)|
|10.||Suttorp, Norbert: 2 articles (12/2015 - 04/2009)|
|1.||Wounds and Injuries (Trauma)
12/01/2008 - "The purpose of the present phase I study was to establish tolerability of MALP-2 when applied into small cutaneous wounds in human beings. "
12/01/2008 - "The effectiveness of MALP-2 in the healing of chronic wounds in humans, e.g. "
12/01/2008 - "An artificial wound was created with a 2-mm diameter skin biopsy punch and a volume of 30 microl MALP-2 (0.125-1 microg) or vehicle control, respectively, was injected intracutaneously into the wound and closed with a water-resistant transparent adhesive. "
09/03/2007 - "Clear signs of local MALP-2 effects were presented by the influx of lymphocytes and monocytes in wound secretions, and abolishment of inhibition of NK activity. "
12/01/2004 - "MALP-2, thus, appears to stimulate the early inflammatory process needed to set in motion the ensuing consecutive natural steps of wound healing resulting in wound closure."
03/01/2004 - "Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model."
09/03/2007 - "This phase I/II trial examined safety and efficacy of the toll-like receptor 2/6 agonist MALP-2 in combination with gemcitabine in patients with incompletely resectable pancreas carcinomas. "
01/01/2013 - "After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. "
12/01/2008 - "In healthy as well as in diabetic patients, MALP-2 induced local inflammation that faded after 48 h. "
09/01/2005 - "These data demonstrate the in vivo efficacy of MALP-2 and IFN-gamma to reduce allergic inflammation and AHR in allergic asthma."
12/01/2015 - "Local pulmonary instillation of MALP-2 in IAV-infected mice 24 h before transnasal pneumococcal infection considerably reduced the bacterial number in the lung tissue without inducing exaggerated inflammation. "
01/01/2013 - "MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock."
09/01/2015 - "Hence, MALP-2 administration with concurrent blocking of COX-2 can be considered as a promising approach in MALP-2-based adjuvant tumor therapies. "
09/01/2015 - "MALP-2 was reported to be involved in natural killer (NK) cell activation and ensuing tumor rejection. "
07/01/2010 - "Furthermore, P2C-RGDS showed higher activity than MALP-2 in inducing migration of DCs to draining lymph node, and in inhibiting tumor growth in vivo. "
03/01/2003 - "Compared with vehicle controls, local administration of MALP-2 parallel to intravenous inoculation of MADB106 mammary adenocarcinoma tumor cells resulted in a significant reduction of lung colony numbers, whereas MALP-2 application 1 or 3 d afterwards was not effective. "
02/01/2012 - "As a consequence, notwithstanding the profound pulmonary immune response induction and in contrast to conclusions drawn from some previous publications, the net extent of experimental metastasis did not change significantly, regardless of the application regimen of MALP-2 prior to, concomitant with or after tumor cell inoculation. "
|1.||Toll-Like Receptor 2
|2.||Toll-Like Receptors (Toll-Like Receptor)
|5.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|7.||Interleukin-6 (Interleukin 6)
|9.||Interleukin-10 (Interleukin 10)